论文信息 - Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel). - 字舞流文

Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel).

V. Sondak | T. Karrison | D. Olson | J. Luke | T. Gajewski | T. Krausz | N. Khushalani | Z. Eroglu | Y. Zha | S. Hallmeyer | B. Brockstein | T. Carll | Madhuri Bajaj